Heron Therapeutics, Inc. (NASDAQ:HRTX) Files An 8-K Regulation FD DisclosureItem 7.01
On August9, 2017, Heron Therapeutics, Inc. (the “Company”) issued a press release announcing initiation of the Phase 3 program for HTX-011 in postoperative pain following successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration, as described in the press release furnished herewith as Exhibit 99.1.
A copy of presentation materials describing a Company update, all or a part of which may be used by the Company in investor or scientific presentations from time to time, is furnished as Exhibit 99.2 hereto. The attached materials have also been posted on the Company’s website at www.herontx.com. The Company does not undertake any obligation to update this presentation.
| Item 7.01 | Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
| 99.1 | Press Release, dated August 9, 2017 |
| 99.2 | Corporate Presentation, dated August 9, 2017 |
HERON THERAPEUTICS, INC. /DE/ ExhibitEX-99.1 2 d398795dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Heron Therapeutics Announces Initiation of Phase 3 Program for HTX-011 in Postoperative Pain Following Successful End-of-Phase 2 Meeting with FDA -Phase 3 Program Expected to Enable Broad Indication- -NDA Filing Planned for 2018- -Final Phase 2 Results Demonstrate Clear Superiority to Bupivacaine Solution across All Surgical Models Evaluated- -Conference Call and Webcast Today at 5:00 p.m. ET- SAN DIEGO,…To view the full exhibit click here
About Heron Therapeutics, Inc. (NASDAQ:HRTX)
Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company’s SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.
